VRPX yields 500000.00% · RYLD yields 12.39%● Live data
📍 VRPX pulled ahead of the other in Year 1
Combined, VRPX + RYLD cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VRPX + RYLD for your $10,000?
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Full VRPX Calculator →The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.
Full RYLD Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.